Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeFronzo, R. A.
Right arrow Articles by Baron, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeFronzo, R. A.
Right arrow Articles by Baron, A. D.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:1092-1100, 2005
© 2005 by the American Diabetes Association, Inc.

Emerging Treatments and Technologies
Original Article

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Ralph A. DeFronzo, MD1, Robert E. Ratner, MD2, Jenny Han, MS3, Dennis D. Kim, MD3, Mark S. Fineman, BS3 and Alain D. Baron, MD3

1 Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas
2 MedStar Research Institute, Hyattsville, Maryland
3 Amylin Pharmaceuticals, San Diego, California

Address correspondence and reprint requests to Alain D. Baron, MD, Amylin Pharmaceuticals, 9360 Towne Centre Dr., Suite 110, San Diego, CA 92121. E-mail: abaron{at}amylin.com

OBJECTIVE—This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses.

RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study at 82 U.S. sites was performed with 336 randomized patients. In all, 272 patients completed the study. The intent-to-treat population baseline was 53 ± 10 years with BMI of 34.2 ± 5.9 kg/m2 and HbA1c of 8.2 ± 1.1%. After 4 weeks of placebo, subjects self-administered 5 µg exenatide or placebo subcutaneously twice daily for 4 weeks followed by 5 or 10 µg exenatide, or placebo subcutaneously twice daily for 26 weeks. All subjects continued metformin therapy.

RESULTS—At week 30, HbA1c changes from baseline ± SE for each group were –0.78 ± 0.10% (10 µg), –0.40 ± 0.11% (5 µg), and +0.08 ± 0.10% (placebo; intent to treat; adjusted P < 0.002). Of evaluable subjects, 46% (10 µg), 32% (5 µg), and 13% (placebo) achieved HbA1c ≤7% (P < 0.01 vs. placebo). Exenatide-treated subjects displayed progressive dose-dependent weight loss (–2.8 ± 0.5 kg [10 µg], –1.6 ± 0.4 kg [5 µg]; P < 0.001 vs. placebo). The most frequent adverse events were gastrointestinal in nature and generally mild to moderate. Incidence of mild to moderate hypoglycemia was low and similar across treatment arms, with no severe hypoglycemia.

CONCLUSIONS—Exenatide was generally well tolerated and reduced HbA1c with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin.

Abbreviations: GLP-1, glucagon-like peptide 1


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

Exenatide: A New Type of Drug to Treat Type 2 Diabetes


This article has been cited by other articles:


Home page
 DTBHome page
Three new drugs for type 2 diabetes
DTB, July 1, 2008; 46(7): 49 - 52.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. M. Picha, M. R. Cunningham, D. J. Drucker, A. Mathur, T. Ort, M. Scully, A. Soderman, T. Spinka-Doms, V. Stojanovic-Susulic, B. A. Thomas, et al.
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor-Dependent Control of Glucose Homeostasis
Diabetes, July 1, 2008; 57(7): 1926 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 Menopause IntHome page
A. Samat, A. Rahim, and A. Barnett
Pharmacotherapy for obesity in menopausal women
Menopause Int, June 1, 2008; 14(2): 57 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. F Van Gaal, S. W Gutkin, and M. A Nauck
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
R. K. Campbell and J. R. White Jr
More Choices Than Ever Before: Emerging Therapies for Type 2 Diabetes
The Diabetes Educator, May 1, 2008; 34(3): 518 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Salehi, B. A. Aulinger, and D. A. D'Alessio
Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Endocr. Rev., May 1, 2008; 29(3): 367 - 379.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
C. L. Martin
Beyond Glycemic Control: The Effects of Incretin Hormones in Type 2 Diabetes
The Diabetes Educator, May 1, 2008; 34(Supplement_3): 66S - 72S.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle
The Obesity Epidemic: Pharmacological Challenges
Mol. Interv., April 1, 2008; 8(2): 82 - 98.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L R Ranganath
Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
J. Clin. Pathol., April 1, 2008; 61(4): 401 - 409.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Klinger, C. Poussin, M.-B. Debril, W. Dolci, P. A. Halban, and B. Thorens
Increasing GLP-1-Induced {beta}-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-{alpha} and DUSP14
Diabetes, March 1, 2008; 57(3): 584 - 593.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. D. Bloom and M. F. Crutchlow
New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. E. Inzucchi and D. K. McGuire
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Circulation, January 29, 2008; 117(4): 574 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
M. J. Fowler
Diabetes Treatment, Part 3: Insulin and Incretins
Clin. Diabetes, January 1, 2008; 26(1): 35 - 39.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
L. M. Siminerio
Approaches to Help People With Diabetes Overcome Barriers for Improved Health Outcomes
The Diabetes Educator, January 1, 2008; 34(1_suppl): 18S - 24S.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. J. Lamont and D. J. Drucker
Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat Fed Mice
Diabetes, January 1, 2008; 57(1): 190 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Rosenstock and V. Fonseca
Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse!
Diabetes Care, November 1, 2007; 30(11): 2972 - 2973.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. N. Davis, D. Johns, D. Maggs, H. Xu, J. H. Northrup, and R. G. Brodows
Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents
Diabetes Care, November 1, 2007; 30(11): 2767 - 2772.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Exploring Treatment Strategies for Type 2 Diabetes
Diabetes Care, October 1, 2007; 30(10): 2737 - 2745.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. C Dunican, A. R Desilets, and J. K Montalbano
Pharmacotherapeutic Options for Overweight Adolescents
Ann. Pharmacother., September 1, 2007; 41(9): 1445 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Heine, R. Brodows, E. G. Maderazo, D. Tarsy, and M. Camilleri
Diabetic Gastroparesis
N. Engl. J. Med., July 26, 2007; 357(4): 418 - 420.
[Full Text] [PDF]

Home page
 JAMAHome page
R. E. Amori, J. Lau, and A. G. Pittas
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
JAMA, July 11, 2007; 298(2): 194 - 206.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
C. W. Spellman
Insulin Therapy for Maximal Glycemic Control in Type 2 Diabetes Mellitus
J Am Osteopath Assoc, July 1, 2007; 107(7): 260 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. Simonsen, S. Pilgaard, C. Orskov, M. M. Rosenkilde, B. Hartmann, J. J. Holst, and C. F. Deacon
Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats
Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G288 - G295.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. A. Bray and F. L. Greenway
Pharmacological Treatment of the Overweight Patient
Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Diabetes Care, June 1, 2007; 30(6): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. E. Dunning and J. E. Gerich
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Endocr. Rev., May 1, 2007; 28(3): 253 - 283.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. T. Haines
Emerging Treatments for Patients With Type 2 Diabetes
The Diabetes Educator, May 1, 2007; 33(Supplement_5): 105S - 110S.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
B. Zinman, B. J. Hoogwerf, S. Duran Garcia, D. R. Milton, J. M. Giaconia, D. D. Kim, M. E. Trautmann, and R. G. Brodows
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Ann Intern Med, April 3, 2007; 146(7): 477 - 485.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Bosi, R. P. Camisasca, C. Collober, E. Rochotte, and A. J. Garber
Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Diabetes Care, April 1, 2007; 30(4): 890 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. B. Knudsen, D. Kiel, M. Teng, C. Behrens, D. Bhumralkar, J. T. Kodra, J. J. Holst, C. B. Jeppesen, M. D. Johnson, J. C. de Jong, et al.
From the Cover: Small-molecule agonists for the glucagon-like peptide 1 receptor
PNAS, January 16, 2007; 104(3): 937 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. G. Murphy and S. R. Bloom
Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?
PNAS, January 16, 2007; 104(3): 689 - 690.
[Full Text] [PDF]

Home page
 JAMAHome page
M. J. Abrahamson
A 74-Year-Old Woman With Diabetes
JAMA, January 10, 2007; 297(2): 196 - 204.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. A. McKennon and R. K. Campbell
The Physiology of Incretin Hormones and the Basis for DPP-4 Inhibitors
The Diabetes Educator, January 1, 2007; 33(1): 55 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
L. E. John, M. P. Kane, R. S. Busch, and R. A. Hamilton
Expanded Use of Exenatide in the Management of Type 2 Diabetes
Diabetes Spectr, January 1, 2007; 20(1): 59 - 63.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R K. Campbell
Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
A. L. Peters and D. Miller
Case Study 2: New Insights: Clinical Pearls for Using Incretin Mimetics in Type 2 Diabetes
The Diabetes Educator, January 1, 2007; 33(Supplement_1): 14S - 19S.
[Full Text] [PDF]

Home page
 Evid. Based Med.Home page
Y. C Kudva and A. Basu
Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitus
Evid. Based Med., December 1, 2006; 11(6): 176 - 176.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K. G. Murphy, W. S. Dhillo, and S. R. Bloom
Gut Peptides in the Regulation of Food Intake and Energy Homeostasis
Endocr. Rev., December 1, 2006; 27(7): 719 - 727.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. L. Williams, D. G. Baskin, and M. W. Schwartz
Leptin Regulation of the Anorexic Response to Glucagon-Like Peptide-1 Receptor Stimulation
Diabetes, December 1, 2006; 55(12): 3387 - 3393.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner
Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 DOC NewsHome page
Overweight Patients a Good Fit for exenatide
DOC News, October 1, 2006; 3(10): 4 - 4.
[Full Text]

Home page
 J Clin PharmacolHome page
D. Soon, P. A. Kothare, H. Linnebjerg, S. Park, E. Yuen, K. F. Mace, and S. D. Wise
Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy asian men.
J. Clin. Pharmacol., October 1, 2006; 46(10): 1179 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. K. Yoo, D. M. Triller, and D. J. Yoo
Exenatide: A New Option for the Treatment of Type 2 Diabetes
Ann. Pharmacother., October 1, 2006; 40(10): 1777 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 DOC NewsHome page
I. B. Hirsch
Pharmacological Treatment of Type 2 Diabetes
DOC News, September 1, 2006; 3(9): 5 - 5.
[Full Text]

Home page
 The Diabetes EducatorHome page
P. S. Odegard, S. M. Setter, and J. L. Iltz
Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.
The Diabetes Educator, September 1, 2006; 32(5): 693 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Nathan, J. B. Buse, M. B. Davidson, R. J. Heine, R. R. Holman, R. Sherwin, and B. Zinman
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, August 1, 2006; 29(8): 1963 - 1972.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
A. B. King, G. Wolfe, and S. Healy
Clinical Observations of Exenatide Treatment
Diabetes Care, August 1, 2006; 29(8): 1984 - 1984.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. D. Green, K. S. Lavery, N. Irwin, F. P. M. O'Harte, P. Harriott, B. Greer, C. J. Bailey, and P. R. Flatt
Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic beta-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 914 - 921.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
R. Hood, V. Valentine, S. Mac, and W. H Polonsky
Use of Exenatide in Patients With Type 2 Diabetes
Diabetes Spectr, July 1, 2006; 19(3): 181 - 186.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L.-X. Li, P. E. MacDonald, D. S. Ahn, G. Y. Oudit, P. H. Backx, and P. L. Brubaker
Role of Phosphatidylinositol 3-Kinase{gamma} in the {beta}-Cell: Interactions with Glucagon-Like Peptide-1
Endocrinology, July 1, 2006; 147(7): 3318 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. L. Baggio, D. Holland, J. Wither, and D. J. Drucker
Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter-Exendin-4 (MT-Exendin) Transgenic Mice
Diabetes, June 1, 2006; 55(6): 1562 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
G. M. Bray
Exenatide
Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. J. Drucker
The evidence for achieving glycemic control with incretin mimetics.
The Diabetes Educator, March 1, 2006; 32(2 Suppl): 72S - 81S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
L. Siminerio
Challenges and strategies for moving patients to injectable medications.
The Diabetes Educator, March 1, 2006; 32(2 Suppl): 82S - 90S.
[Full Text] [PDF]

Home page
 GutHome page
M Horowitz and M A Nauck
To be or not to be--an incretin or enterogastrone?
Gut, February 1, 2006; 55(2): 148 - 150.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. C. Riddle and D. J. Drucker
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Diabetes Care, February 1, 2006; 29(2): 435 - 449.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Park, X. Dong, T. L. Fisher, S. Dunn, A. K. Omer, G. Weir, and M. F. White
Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic beta Cell Growth and Function
J. Biol. Chem., January 13, 2006; 281(2): 1159 - 1168.
[Abstract] [Full Text] [PDF]